Gene Sequencing, Genetic Disease and Genetics

Gene therapy specialist bluebird exits “untenable” European market

pharmaphorum

AUGUST 10, 2021

Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. market and will wind down in Europe.

Gene Therapy

Gene Therapy Gene Marketing Genetic Disease

Next Generation Sequencing (NGS) Library Preparation Kits Market: Current Scenario and Future Potential

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing

Marketing Gene Sequencing DNA Genome

SparingVision raises €75m for eye disease gene therapies

pharmaphorum

SEPTEMBER 14, 2022

Meanwhile, a third gene therapy candidate – SPVN30, which combines the gene sequences in SPVN06 and SPVN20 – is in early development for RP. The post SparingVision raises €75m for eye disease gene therapies appeared first on.

Gene Therapy

Gene Therapy Gene Gene Sequencing Gene Editing

Clinical Research Informer

Gene therapy specialist bluebird exits “untenable” European market

Next Generation Sequencing (NGS) Library Preparation Kits Market: Current Scenario and Future Potential

SparingVision raises €75m for eye disease gene therapies

Stay Connected